Jonas Cicenas
Overview
Explore the profile of Jonas Cicenas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J
Cancers (Basel)
. 2017 Apr;
9(5).
PMID: 28452926
Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related...
12.
Stankevicius V, Kunigenas L, Stankunas E, Kuodyte K, Strainiene E, Cicenas J, et al.
Biochem Biophys Res Commun
. 2017 Feb;
484(4):726-733.
PMID: 28174005
Numerous lines of evidence support the hierarchical model of cancer development and tumor initiation. According to the theory, cancer stem cells play a crucial role in the formation of the...
13.
Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K, et al.
Med Oncol
. 2017 Jan;
34(2):26.
PMID: 28074351
Cancers are the group of diseases, which arise because of the uncontrolled behavior of some of the genes in our cells. There are possibilities of gene amplifications, overexpressions, deletions and...
14.
Tumas J, Kvederaviciute K, Petrulionis M, Kurlinkus B, Rimkus A, Sakalauskaite G, et al.
Med Oncol
. 2016 Nov;
33(12):133.
PMID: 27807722
Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative...
15.
Cicenas J, Cicenas E
Med Oncol
. 2016 Apr;
33(5):43.
PMID: 27038473
Inhibitors that impact function of kinases are valuable both for the biological research as well as therapy of kinase-associated diseases, such as different cancers. There are quite a number of...
16.
Cicenas J
J Cancer Res Clin Oncol
. 2016 Mar;
142(9):1995-2012.
PMID: 26932147
Compounds that affect enzymatic function of kinases are valuable for the understanding of the complex biochemical processes in cells. Aurora kinases (AURKs) play a key role in the control of...
17.
Ger M, Kaupinis A, Nemeikaite-ceniene A, Sarlauskas J, Cicenas J, cenas N, et al.
Biochim Biophys Acta
. 2015 Nov;
1864(2):219-32.
PMID: 26596252
Nad(p)h: quinone oxidoreductase, an enzyme expressed at high levels in many types of tumors. Here we investigated the potential mechanisms of acquired RH1 drug resistance in cancer cells by applying...
18.
Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, et al.
Ann Transl Med
. 2015 Jul;
3(10):135.
PMID: 26207228
Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine inhibitor, which inhibits CDK1, CDK2,...
19.
Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, et al.
Cancers (Basel)
. 2014 Oct;
6(4):2224-42.
PMID: 25349887
Uncontrolled proliferation is the hallmark of cancer and other proliferative disorders and abnormal cell cycle regulation is, therefore, common in these diseases. Cyclin-dependent kinases (CDKs) play a crucial role in...
20.
Cicenas J, Kung W, Eppenberger U, Eppenberger-Castori S
Cancers (Basel)
. 2013 Nov;
2(1):153-64.
PMID: 24281038
The SH2 domain-containing adaptor protein ShcA is a proto-oncogene involved in growth factor receptor signaling. The role of phosphorylated ShcA is to link receptor tyrosine kinases with the SH2-containing adaptor...